Cas:6372-42-5 Cyclohexyl(diphenyl)phosphine manufacturer & supplier

Chemical Name:Cyclohexyl(diphenyl)phosphine

CAS.NO:6372-42-5

Synonyms:cyclohexyl(diphenyl)phosphane;EINECS 228-904-2;Phosphine, cyclohexyldiphenyl-;MFCD00046360;Cyclohexyl(diphenyl)phosphine;Cyclohexyl diphenylphosphine

Molecular Formula:C₁₈H₂₁P

Molecular Weight:268.333

HS Code:2902909090

Physical and Chemical Properties:

Melting point:58-62 °C(lit.)

Boiling point:374.0±11.0 °C at 760 mmHg

Density:N/A

Index of Refraction:

PSA:13.59000

Exact Mass:268.138092

LogP:6.38

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:NONH for all modes of transpor

Packing Group:

Contact us for information like cyclohexyl(diphenyl)phosphane chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,Cyclohexyl diphenylphosphine physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,Cyclohexyl diphenylphosphine Use and application,MFCD00046360 technical grade,usp/ep/jp grade.

Related News: Lilly has pledged to address the problems, and said none of them affected drugs in the market. The FDA, which has taken no public action, did not respond to requests for comment. Cyclohexyl(diphenyl)phosphine manufacturer South Korea and Japan are barring noncitizens who traveled recently to Hubei, the province at the center of the outbreak. Cyclohexyl(diphenyl)phosphine supplier This is particularly important in reducing overall disease burden. Moreover, this strategic decision will not only strengthen our diabetes portfolio but also help consolidate our position as the fastest-growing player in the anti-diabetes segment, Mankind Pharma Director of Marketing Sanjay Koul said in a statement. Cyclohexyl(diphenyl)phosphine vendor Lilly has pledged to address the problems, and said none of them affected drugs in the market. The FDA, which has taken no public action, did not respond to requests for comment. Cyclohexyl(diphenyl)phosphine factory This is particularly important in reducing overall disease burden. Moreover, this strategic decision will not only strengthen our diabetes portfolio but also help consolidate our position as the fastest-growing player in the anti-diabetes segment, Mankind Pharma Director of Marketing Sanjay Koul said in a statement.